Streetbeat News

WGS

GeneDx Holdings Corp.

http://www.genedx.com

Industry

Medical - Healthcare Information Services

GeneDx Holdings Corp. is a patient centered health intelligence company. It engages in transforming healthcare by applying AI and machine learning to multidimensional, longitudinal clinical and genomic data to build dynamic models of human health and defining optimal, individualized health trajectories. The firm, through its Centrellis health intelligence platform, generates a more complete understanding of disease and wellness and provides science-driven solutions to the most pressing medical needs. The company was founded by Eric Schadt in October 2015 and is headquartered in Stamford, CT.

Open

90.93

Mkt cap

2.8B

Volume

915K

High

101.19

P/E Ratio

-50.76

52-wk high

115.60

Low

90.20

Div yield

N/A

52-wk low

7.72

In Friday's intraday session, several healthcare stocks experienced significant movements. Akso Health Group (AHG), Elevation Oncology (ELEV), Y-mAbs Therapeutics (YMAB), Atreca (BCEL), Alaunos Therapeutics (TCRT), and ASLAN Pharma (ASLN) saw their stock prices increase, with gains ranging from 13.77% to 29.2%. Conversely, Cyclacel Pharmaceuticals (CYCC), NexImmune (NEXI), MAIA Biotechnology (MAIA), Avalo Therapeutics (AVTX), GeneDx Hldgs (WGS), and Seelos Therapeutics (SEEL) faced declines between 12.27% and 19.4%.

Portfolio Pulse from Benzinga Insights

January 12, 2024 | 5:31 pm

Health care stocks experienced significant movement in Wednesday's intraday session. Sana Biotechnology (SANA) led the gainers with a 45.2% increase, while DocGo (DCGO) saw the largest decline among the losers, dropping 35.2%. Other notable movers included Amarin Corp (AMRN), Vicarious Surgical (RBOT), and TG Therapeutics (TGTX). Market capitalizations were also highlighted, indicating the size of each company.

Portfolio Pulse from Benzinga Insights

January 10, 2024 | 5:31 pm

GeneDx shares have risen following the announcement of their preliminary financial results for 2023. The company's performance update appears to have positively influenced investor sentiment.

Portfolio Pulse from Benzinga Newsdesk

January 08, 2024 | 6:56 pm

GeneDx Holdings Corp. (NASDAQ:WGS) announced preliminary financial results for Q4 and FY 2023, exceeding revenue expectations. Q4 revenue is expected to be at least $58M, surpassing the $49.06M estimate, and FY23 revenue is projected to be at least $203M, above the $188.3M estimate. The company reported significant year-over-year growth in exome and genome test revenue and reduced cash burn. GeneDx reiterates its path to profitability by 2025 and will discuss detailed financial and operating results in a conference call on February 20, 2024.

Portfolio Pulse from Benzinga Newsdesk

January 08, 2024 | 2:14 pm

GeneDx (NASDAQ:WGS) announced new data supporting exome sequencing over multi-gene panels for epilepsy diagnosis, to be presented at the AES annual meeting. The study of 22,500 individuals showed a 25% diagnosis rate with exome sequencing, higher than the 19% with multi-gene panels. 78% of those diagnosed had prior testing, indicating exome sequencing's superior diagnostic ability. Over half of seizure-related genes are not on many epilepsy panels. 11% of positive diagnoses from exome sequencing involved treatment-related genes. GeneDx will also present data on better insurance coverage for exome sequencing. The NSGC and AES recommend exome sequencing as a first-tier test for unexplained epilepsy. GeneDx will host a symposium at the conference discussing the benefits of exome sequencing for epilepsy patients.

Portfolio Pulse from Benzinga Newsdesk

December 01, 2023 | 1:31 pm

During Friday's intraday session, several healthcare stocks experienced significant movements. GeneDx Holdings (WGS) saw a 39.7% increase, while Evelo Biosciences (EVLO) dropped 19.7%. Other notable gainers include Scilex Holding (SCLX), Modular Medical (MODD), Sight Sciences (SGHT), Gyre Therapeutics (GYRE), and Pasithea Therapeutics (KTTA). On the losing side, Leap Therapeutics (LPTX), SenesTech (SNES), Virios Therapeutics (VIRI), MSP Recovery (LIFW), and Biophytis (BPTS) saw declines in their stock prices.

Portfolio Pulse from Benzinga Insights

November 24, 2023 | 5:31 pm

Insiders at Plus Therapeutics, Inc. (PSTV), GeneDx Holdings Corp. (WGS), and Socket Mobile, Inc. (SCKT) have recently acquired shares of their respective companies. PSTV posted downbeat quarterly sales and announced a share repurchase program. WGS posted upbeat quarterly sales. SCKT posted a wider-than-expected third-quarter loss.

Portfolio Pulse from Lisa Levin

November 09, 2023 | 1:51 pm

Goldman Sachs analyst Matthew Sykes has maintained a Neutral rating on GeneDx Hldgs (NASDAQ:WGS) and lowered the price target from $7 to $6.

Portfolio Pulse from Benzinga Newsdesk

November 01, 2023 | 1:27 pm

The article lists the stocks that gained and lost in Tuesday's mid-day session. Notable gainers include SciSparc Ltd., Cardio Diagnostics Holdings, Inc., and Verve Therapeutics, Inc. due to positive news such as patent acceptance and contract acquisition. On the other hand, Kintara Therapeutics, Inc., Galera Therapeutics, Inc., and reAlpha Tech Corp. were among the biggest losers due to negative developments like unsuccessful drug trials and poor financial results.

Portfolio Pulse from Lisa Levin

October 31, 2023 | 5:36 pm

GeneDx Holdings reported its Q3 financial results, which led to a decrease in the company's share prices.

Portfolio Pulse from Benzinga Newsdesk

October 31, 2023 | 3:39 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.